CliffBio
small molecule

VASOCON-A

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameVASOCON-A
Active ingredientANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE
Strength0.5%;0.05%
Dosage formSOLUTION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalJuly 1994
Marketing statusDISCN

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.